Fasinumab

Fasinumab is a human monoclonal antibody designed for the treatment of pain, particularly osteoarthritis pain and chronic low back pain. It is developed by Regeneron Pharmaceuticals and Teva Pharmaceutical Industries.

Mechanism of Action

Fasinumab works by targeting and inhibiting nerve growth factor (NGF), a protein that plays a key role in the regulation of pain signals. By blocking NGF, Fasinumab can potentially reduce pain in patients with osteoarthritis and chronic low back pain.

Clinical Trials

Fasinumab has undergone several clinical trials to evaluate its safety and efficacy. In Phase II and III trials, Fasinumab demonstrated a significant reduction in pain and improved physical function in patients with osteoarthritis of the knee or hip. However, the trials also revealed a higher rate of joint-related adverse events in Fasinumab-treated patients compared to placebo.

Potential Side Effects

The most common side effects of Fasinumab include joint swelling, pain, and peripheral edema. Serious side effects may include joint destruction, which can lead to the need for joint replacement surgery.

Current Status

As of 2021, Fasinumab is still under investigation and has not yet been approved by the Food and Drug Administration (FDA) for use in the United States.

See Also

• Osteoarthritis
• Chronic low back pain
• Nerve growth factor
• Clinical trials
• Regeneron Pharmaceuticals
• Teva Pharmaceutical Industries